Works matching IS 14363291 AND DT 2022 AND VI 25 AND IP 3
Results: 16
A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 3, p. 619, doi. 10.1007/s10120-022-01286-w
- By:
- Publication type:
- Article
Intracellular MUC20 variant 2 maintains mitochondrial calcium homeostasis and enhances drug resistance in gastric cancer.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 3, p. 542, doi. 10.1007/s10120-022-01283-z
- By:
- Publication type:
- Article
rs2671655 single nucleotide polymorphism modulates the risk for gastric cancer in Helicobacter pylori–infected individuals: a genome-wide association study in the Korean population.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 3, p. 573, doi. 10.1007/s10120-022-01285-x
- By:
- Publication type:
- Article
Lysosomal-associated membrane protein family member 5 promotes the metastatic potential of gastric cancer cells.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 3, p. 558, doi. 10.1007/s10120-022-01284-y
- By:
- Publication type:
- Article
Aspirin use in relation to long-term survival after gastrectomy for gastric adenocarcinoma.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 3, p. 652, doi. 10.1007/s10120-022-01282-0
- By:
- Publication type:
- Article
Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 3, p. 640, doi. 10.1007/s10120-022-01280-2
- By:
- Publication type:
- Article
LRG1 mediated by ATF3 promotes growth and angiogenesis of gastric cancer by regulating the SRC/STAT3/VEGFA pathway.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 3, p. 527, doi. 10.1007/s10120-022-01279-9
- By:
- Publication type:
- Article
A rare gastric lesion: diminutive, well-differentiated, Grade 3, type 3 gastric neuroendocrine tumor with extremely high ki-67 index removed en bloc under endoscopy.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16).
- Published in:
- Gastric Cancer, 2022, v. 25, n. 3, p. 609, doi. 10.1007/s10120-021-01276-4
- By:
- Publication type:
- Article
Crosstalk between cancer-associated fibroblasts and immune cells in peritoneal metastasis: inhibition in the migration of M2 macrophages and mast cells by Tranilast.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 3, p. 515, doi. 10.1007/s10120-021-01275-5
- By:
- Publication type:
- Article
Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 3, p. 598, doi. 10.1007/s10120-021-01274-6
- By:
- Publication type:
- Article
CAF promotes chemoresistance through NRP2 in gastric cancer.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 3, p. 503, doi. 10.1007/s10120-021-01270-w
- By:
- Publication type:
- Article
Gastric cancer exosomes contribute to the field cancerization of gastric epithelial cells surrounding gastric cancer.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 3, p. 490, doi. 10.1007/s10120-021-01269-3
- By:
- Publication type:
- Article
Development of the PERI-Gastric (PEritoneal Recurrence Index) and PERI-Gram (Peritoneal Recurrence Index NomoGRAM) for predicting the risk of metachronous peritoneal carcinomatosis after gastrectomy with curative intent for gastric cancer.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 3, p. 629, doi. 10.1007/s10120-021-01268-4
- By:
- Publication type:
- Article
Risk factors for gastric cancer in Japan in the 2010s: a large, long-term observational study.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 3, p. 481, doi. 10.1007/s10120-021-01273-7
- By:
- Publication type:
- Article
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS).
- Published in:
- Gastric Cancer, 2022, v. 25, n. 3, p. 586, doi. 10.1007/s10120-021-01271-9
- By:
- Publication type:
- Article